The Rak/Frk tyrosine kinase associates with and internalizes the epidermal growth factor receptor

Oncogene

Volumn 33, Issue 3, 2014, Pages 326-335

  Jin, L ^a   Craven, R J ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

EGFR; Frk; Rak; SH2; SH3; signaling; tyrosine kinase

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FYN RELATED KINASE; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; PROTEIN SH2; PROTEIN SH3; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ARTICLE; BIOTINYLATION; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENICITY; CELL MEMBRANE; COMPLEX FORMATION; CONTROLLED STUDY; EXON; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; LUNG CANCER; OVARY CANCER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

CELL LINE, TUMOR; CELL MEMBRANE; ENDOCYTOSIS; EPIDERMAL GROWTH FACTOR; EXONS; HEK293 CELLS; HUMANS; IMMUNOBLOTTING; MICROSCOPY, FLUORESCENCE; MUTATION; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAINS;

EID: 84892631469     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.589     Document Type: Article

References (45)

1. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010; 141: 1117-1134.
2. Ganti AK. Epidermal growth factor receptor signaling in nonsmall cell lung cancer. Cancer Invest 2010; 28: 515-525.
3. Sequist LV, Lynch TJ. EGFR tyrosine kinase inhibitors in lung cancer: an evolving story. Annu Rev Med 2008; 59: 429-442.
4. Arteaga CL. ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res 2003; 284: 122-130.
5. Rivera F, Vega-Villegas ME, Lopez-Brea MF. Cetuximab, its clinical use and future perspectives. Anticancer Drugs 2008; 19: 99-113.
6. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
7. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
8. Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009; 28(Suppl 1): S24-S31.
9. Sorkin A, Goh LK. Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res 2008; 314: 3093-3106.
10. Keilhack H, Tenev T, Nyakatura E, Godovac-Zimmermann J, Nielsen L, Seedorf K et al. Phosphotyrosine 1173 mediates binding of the protein-tyrosine phosphatase SHP-1 to the epidermal growth factor receptor and attenuation of receptor signaling. J Biol Chem 1998; 273: 24839-24846.
11. Hsu JM, Chen CT, Chou CK, Kuo HP, Li LY, Lin CY et al. Crosstalk between Arg 1175 methylation and Tyr 1173 phosphorylation negatively modulates EGFR-mediated ERK activation. Nat Cell Biol 2011; 13: 174-181.
12. Tanos B, Pendergast AM. Abl tyrosine kinase regulates endocytosis of the epidermal growth factor receptor. J Biol Chem 2006; 281: 32714-32723.
13. Giubellino A, Burke Jr TR, Bottaro DP. Grb2 signaling in cell motility and cancer. Expert Opin Ther Targets 2008; 12: 1021-1033.
14. Lowenstein EJ, Daly RJ, Batzer AG, Li W, Margolis B, Lammers R et al. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell 1992; 70: 431-442.
15. Smithgall TE. SH2 and SH3 domains: potential targets for anti-cancer drug design. J Pharmacol Toxicol Methods 1995; 34: 125-132.
16. Cance WG, Craven RJ, Weiner TM, Liu ET. Novel protein kinases expressed in human breast cancer. Int J Cancer 1993; 54: 571-577.
17. Cance WG, Craven RJ, Bergman M, Xu L, Alitalo K, Liu ET. Rak, a novel nuclear tyrosine kinase expressed in epithelial cells. Cell Growth Differ 1994; 5: 1347-1355.
18. Lee J, Wang Z, Luoh SM, Wood WI, Scadden DT. Cloning of FRK, a novel human intracellular SRC-like tyrosine kinase-encoding gene. Gene 1994; 138: 247-251.
19. Serfas MS, Tyner AL. Brk, Srm, Frk, and Src42A form a distinct family of intracellular Src-like tyrosine kinases. Oncol Res 2003; 13: 409-419.
20. Boggon TJ, Eck MJ. Structure and regulation of Src family kinases. Oncogene 2004; 23: 7918-7927.
21. Craven RJ, Cance WG, Liu ET. The nuclear tyrosine kinase Rak associates with the retinoblastoma protein pRb. Cancer Res 1995; 55: 3969-3972.
22. Meyer T, Xu L, Chang J, Liu ET, Craven RJ, Cance WG. Breast cancer cell line proliferation blocked by the Src-related Rak tyrosine kinase. Int J Cancer 2003; 104: 139-146.
23. Yim EK, Peng G, Dai H, Hu R, Li K, Lu Y et al. Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell 2009; 15: 304-314.
24. Thuveson M, Albrecht D, Zurcher G, Andres AC, Ziemiecki A. iyk, a novel intracellular protein tyrosine kinase differentially expressed in the mouse mammary gland and intestine. Biochem Biophys Res Commun 1995; 209: 582-589.
25. Berclaz G, Altermatt HJ, Rohrbach V, Dreher E, Ziemiecki A, Andres AC. Hormonedependent nuclear localization of the tyrosine kinase iyk in the normal human breast epithelium and loss of expression during carcinogenesis. Int J Cancer 2000; 85: 889-894.
26. Oberg-Welsh C, Anneren C, Welsh M. Mutation of C-terminal tyrosine residues Y497/Y504 of the Src-family member Bsk/Iyk decreases NIH3T3 cell proliferation. Growth Factors 1998; 16: 111-124.
27. Chandrasekharan S, Qiu TH, Alkharouf N, Brantley K, Mitchell JB, Liu ET. Characterization of mice deficient in the Src family nonreceptor tyrosine kinase Frk/rak. Mol Cell Biol 2002; 22: 5235-5247.
28. Georgescu MM. PTEN tumor suppressor network in PI3K-Akt pathway control. Genes Cancer 2010; 1: 1170-1177.
29. Emlet DR, Moscatello DK, Ludlow LB, Wong AJ. Subsets of epidermal growth factor receptors during activation and endocytosis. J Biol Chem 1997; 272: 4079-4086.
30. Katso RM, Pardo OE, Palamidessi A, Franz CM, Marinov M, De Laurentiis A et al. Phosphoinositide 3-kinase C2beta regulates cytoskeletal organization and cell migration via Rac-dependent mechanisms. Mol Biol Cell 2006; 17: 3729-3744.
31. Jin G, Jeon HS, Yang E, Park JY. Mutation analysis of the FRK gene in non-small cell lung cancers. Lung Cancer 2011; 71: 115-117.
32. Goeze A, Schluns K, Wolf G, Thasler Z, Petersen S, Petersen I. Chromosomal imbalances of primary and metastatic lung adenocarcinomas. J Pathol 2002; 196: 8-16.
33. Brauer PM, Tyner AL. Building a better understanding of the intracellular tyrosine kinase PTK6-BRK by BRK. Biochim Biophys Acta 2010; 1806: 66-73.
34. Haegebarth A, Bie W, Yang R, Crawford SE, Vasioukhin V, Fuchs E et al. Protein tyrosine kinase 6 negatively regulates growth and promotes enterocyte differentiation in the small intestine. Mol Cell Biol 2006; 26: 4949-4957.
35. Zheng Y, Asara JM, Tyner AL. Protein-tyrosine kinase 6 promotes peripheral adhesion complex formation and cell migration by phosphorylating p130 CRKassociated substrate. J Biol Chem 2012; 287: 148-158.
36. Palka-Hamblin HL, Gierut JJ, Bie W, Brauer PM, Zheng Y, Asara JM et al. Identification of beta-catenin as a target of the intracellular tyrosine kinase PTK6. J Cell Sci 2010; 123(Part 2): 236-245.
37. Zheng Y, Peng M, Wang Z, Asara JM, Tyner AL. Protein tyrosine kinase 6 directly phosphorylates AKT and promotes AKT activation in response to epidermal growth factor. Mol Cell Biol 2010; 30: 4280-4292.
38. Li X, Lu Y, Liang K, Hsu JM, Albarracin C, Mills GB et al. Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR. Oncogene 2012; 31: 4372-4383.
39. Kuriyan J, Cowburn D. Modular peptide recognition domains in eukaryotic signaling. Annu Rev Biophys Biomol Struct 1997; 26: 259-288.
40. Buday L, Downward J. Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor. Cell 1993; 73: 611-620.
41. Okutani T, Okabayashi Y, Kido Y, Sugimoto Y, Sakaguchi K, Matuoka K et al. Grb2/Ash binds directly to tyrosines 1068 and 1086 and indirectly to tyrosine 1148 of activated human epidermal growth factor receptors in intact cells. J Biol Chem 1994; 269: 31310-31314.
42. Greulich H, Chen TH, Feng W, Janne PA, Alvarez JV, Zappaterra M et al. Oncogenic transformation by inhibitor-sensitive and-resistant EGFR mutants. PLoS Med 2005; 2: e313.
43. Furukawa M, Nagatomo I, Kumagai T, Yamadori T, Takahashi R, Yoshimura M et al. Gefitinib-sensitive EGFR lacking residues 746-750 exhibits hypophosphorylation at tyrosine residue 1045, hypoubiquitination, and impaired endocytosis. DNA Cell Biol 2007; 26: 178-185.
44. Padron D, Sato M, Shay JW, Gazdar AF, Minna JD, Roth MG. Epidermal growth factor receptors with tyrosine kinase domain mutations exhibit reduced Cbl association, poor ubiquitylation, and down-regulation but are efficiently internalized. Cancer Res 2007; 67: 7695-7702.
45. Crudden G, Loesel R, Craven RJ. Overexpression of the cytochrome p450 activator hpr6 (heme-1 domain protein/human progesterone receptor) in tumors. Tumor Biol 2005; 26: 142-146.